Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Alflutinib (AST2818) in Healthy Male Volunteers
NCT03926182Phase 1Completed
- Sponsor
- Allist Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Allist Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration of AST2818 at 504 hours, Area Under the Plasma Concentration-Time Curve of AST2818 at 504 hours and 1 more. Started Feb 2019; status: completed.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03926182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926182.